PMID- 26110071
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150625
LR  - 20200930
IS  - 2150-0878 (Print)
IS  - 2150-0886 (Electronic)
IS  - 2150-0878 (Linking)
VI  - 5
IP  - 4
DP  - 2014 Jul-Aug
TI  - Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies.
PG  - 269-79
AB  - Lenalidomide is an oral immunomodulatory agent approved in relapsed multiple 
      myeloma with dexamethasone, for transfusion-dependent anemia in myelodysplastic 
      syndrome associated with deletion 5q, and in relapsed/progressive mantle cell 
      lymphoma following bortezomib. In recent clinical trials, lenalidomide has shown 
      promising activity in hematologic malignancies, including chronic lymphocytic 
      leukemia (CLL) and non-Hodgkin lymphoma (NHL). Starting doses and dosing 
      schedules vary by malignancy, with lenalidomide started at a lower dose for CLL 
      than for NHL or multiple myeloma. Certain adverse events (AEs) are common across 
      tumor types (e.g., neutropenia, thrombocytopenia, fatigue), whereas others are 
      more often associated with CLL patients (e.g., tumor lysis syndrome and tumor 
      flare reaction). Effective management requires awareness of these differences as 
      well as appropriate prophylaxis, monitoring, and treatment of AEs. This article 
      reviews the efficacy and safety of lenalidomide in CLL and NHL, focusing on 
      approaches for the advanced practitioner to improve patient quality of life 
      through optimal management of side effects. With these steps, lenalidomide can be 
      administered safely, at the best starting doses and with minimal dose 
      interruptions or reductions across hematologic malignancies.
FAU - Blumel, Susan
AU  - Blumel S
AD  - University of Nebraska Medical Center, Omaha, Nebraska, and MD Anderson Cancer 
      Center, Houston, Texas.
FAU - Broadway-Duren, Jackie
AU  - Broadway-Duren J
AD  - University of Nebraska Medical Center, Omaha, Nebraska, and MD Anderson Cancer 
      Center, Houston, Texas.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Adv Pract Oncol
JT  - Journal of the advanced practitioner in oncology
JID - 101550346
PMC - PMC4457182
EDAT- 2015/06/26 06:00
MHDA- 2015/06/26 06:01
PMCR- 2014/07/01
CRDT- 2015/06/26 06:00
PHST- 2015/06/26 06:00 [entrez]
PHST- 2015/06/26 06:00 [pubmed]
PHST- 2015/06/26 06:01 [medline]
PHST- 2014/07/01 00:00 [pmc-release]
AID - 10.6004/jadpro.2014.5.4.4 [doi]
PST - ppublish
SO  - J Adv Pract Oncol. 2014 Jul-Aug;5(4):269-79. doi: 10.6004/jadpro.2014.5.4.4.